Table 1. Clinical features of patients in the ROMG and GOMG groups.
| ROMG (n=88) | GOMG (n=24) | p | |
|---|---|---|---|
| Age at onset, years | 45.3±17.0 | 52.2±12.4 | 0.032 |
| Male | 43 (50.0) | 14 (58.3) | 0.469 |
| Duration from onset to MG diagnosis, months | 2.9 [1.4–10.0] | 1.9 [0.7–4.6] | 0.082 |
| Follow-up duration, months | 38.4 [19.0–89.0] | - | |
| Duration from onset to conversion to generalized MG, months | - | 15.9 [5.2–30.8] | |
| AChR-antibody positivity, >0.5 nmol/L | 57 (66.3) | 20 (83.3) | 0.100 |
| Titer of AChR antibody, nmol/L | 5.0±3.7 | 9.1±3.6 | <0.001 |
| Positivity in neostigmine challenge test | 62 (87.3) | 19 (90.5) | 0.725 |
| Thymus on chest CT* | 0.449 | ||
| Normal | 45 (57.0) | 11 (45.8) | |
| Thymic hyperplasia | 20 (25.3) | 6 (25.0) | |
| Thymoma | 14 (17.7) | 7 (29.2) | |
| Thymectomy | 17 (19.3) | 9 (37.5) | 0.061 |
| Thymoma confirmed by pathology | 14 (15.9) | 7 (29.2) | 0.140 |
| Treatment† | |||
| Pyridostigmine | 83 (94.3) | 24 (100) | 0.227 |
| Oral prednisolone | 51 (58.0) | 8 (33.3) | 0.039 |
| Use of immunosuppressive agent | 3 (3.4) | 2 (8.3) | 0.291 |
Data are mean±SD, median [interquartile range], or n (%) values.
*Chest CT was performed in 79 patients in the ROMG group, †Medication administration within 1 year from the diagnosis in the ROMG group or before conversion in the GOMG group.
AChR: acetylcholine receptor, CT: computed tomography, GOMG: symptom conversion to generalized MG, MG: myasthenia gravis, ROMG: remained as ocular MG.